Previous 10 | Next 10 |
Kezar Life Sciences, Inc. (Nasdaq:KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced its Chief Executive Officer, John Fowler, will present a corporate overview at the BIO CEO &...
Kezar is a founder-driven company with deep expertise in proteasome and drug development, and they have a track record of approved medicines. The company's lead asset, KZR-616, is a first-in-class inhibitor of the immunoproteasome with the potential to become a pipeline-in-a-pill for ...
Kezar Life Sciences, Inc. (Nasdaq:KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced its Chief Executive Officer, John Fowler, will present a corporate overview at the H.C. Wainwrig...
Gainers: [[MDWD]] +19.5%. [[KZR]] +14.3%. [[PQG]] +9%. [[GOSS]] +4%. [[RC]] +2.6%.Losers: [[MESO]] -7.6%. [[CELP]] -5.3%. [[GDS]] -5.1%. [[EAF]] -4.2%. [[RUBY]] -4%. For further details see: MESO, EAF, RC and MDWD among after-hours movers
Kezar Life Sciences (KZR) has been added to the NASDAQ Biotech Index, effective Dec. 21, 2020 before market open.In the past year, the stock has gained 103.7% vs. 23.8% gains in the iShares Nasdaq Biotechnology ETF (IBB).Press Release For further details see: Kezar Life Sciences selecte...
Kezar Life Sciences, Inc . (Nasdaq: KZR ), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that it has been added to the NASDAQ Biotech Index (Nasdaq: NBI), effective prior to ...
Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced members of the executive team will present during upcoming virtual investor conferences. The de...
Kezar is a young company with two candidates in clinical development. Development programs with broad therapeutic potential. Upcoming catalysts in 2021 through 2022. The company is well-funded with cash runway through 2022. For further details see: Kezar Life Science...
Kezar Life Sciences (KZR): Q3 GAAP EPS of -$0.23 misses by $0.02.Cash, cash equivalents and marketable securities of $150M.Press Release For further details see: Kezar Life Sciences EPS misses by $0.02
FDA grants two Orphan Drug Designations to KZR-616 for the treatment of Dermatomyositis (DM) and Polymyositis (PM) KZR-616 clinical and pre-clinical data continues to support its potential to positively affect multiple drivers of immune-mediated diseases KZ...
News, Short Squeeze, Breakout and More Instantly...
Kezar Life Sciences Inc. Company Name:
KZR Stock Symbol:
NASDAQ Market:
Kezar Life Sciences Inc. Website:
Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer, today announced that Chris Kirk, Co-founder and Chief Executive Officer, will participate in a fireside chat at...
PALIZADE Phase 2b clinical trial of zetomipzomib in patients with active lupus nephritis actively enrolling; reiterating guidance of topline data in mid-2026 PORTOLA Phase 2a clinical trial of zetomipzomib in patients with autoimmune hepatitis actively enrolling; reiterating guidance of t...
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...